Increased Expression of Vascular Endothelial Growth Factor in Hepatocellular Carcinoma after Transcatheter Arterial Chemoembolization

References

• Unoura M, Kaneko S, Matsushita E, Shimoda A, Takeuchi M, Adachi H, et al. High-risk groups and screening strategies for early detection of hepatocellular carcinoma in patients with chronic liver disease. Hepatogastroenterology 1993; 40: 305–10
   PubMedGoogle Scholar
• Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001; 2: 533–43
   PubMed Web of Science ®Google Scholar
• El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340: 745–50
   PubMed Web of Science ®Google Scholar
• Qin LX, Tang ZY. The prognostic significance of clinical and pathological features in hepatocellular carcinoma. World J Gastroenterol 2002; 8: 193–9
   PubMed Web of Science ®Google Scholar
• Parks RW, Garden OJ. Liver resection for cancer. World J Gastroenterol 2001; 7: 766–71
   PubMed Web of Science ®Google Scholar
• Sun HC, Tang ZY. Preventive treatments for recurrence after curative resection of hepatocellular carcinoma—a literature review of randomized control trials. World J Gastroenterol 2003; 9: 635–40
   PubMed Web of Science ®Google Scholar
• Ernst O, Sergent G, Mizrahi D, Delemazure O, Paris JC, L'Hermine C. Treatment of hepatocellular carcinoma by transcatheter arterial chemoembolization: comparison of planned periodic chemoembolization and chemoembolization based on tumor response. Am J Roentgenol 1999; 172: 59–64
   PubMed Web of Science ®Google Scholar
• Llado L, Virgili J, Figueras J, Valls C, Dominguez J, Rafecas A, et al. A prognostic index of the survival of patients with unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization. Cancer 2000; 88: 50–7
   PubMed Web of Science ®Google Scholar
• Sumie S, Yamashita F, Ando E, Tanaka M, Yano Y, Fukumori K, et al. Interventional radiology for advanced hepatocellular carcinoma: comparison of hepatic artery infusion chemotherapy and transcatheter arterial lipiodol chemoembolization. Am J Roentgenol 2003; 181: 1327–34
   PubMed Web of Science ®Google Scholar
• Seki T, Tamai T, Nakagawa T, Imamura M, Nishimura A, Yamashiki N, et al. Combination therapy with transcatheter arterial chemoembolization and percutaneous microwave coagulation therapy for hepatocellular carcinoma. Cancer 2000; 89: 1245–51
   PubMed Web of Science ®Google Scholar
• Ueno K, Miyazono N, Inoue H, Nishida H, Kanetsuki I, Nakajo M. Transcatheter arterial chemoembolization therapy using iodized oil for patients with unresectable hepatocellular carcinoma: evaluation of three kinds of regimens and analysis of prognostic factors. Cancer 2000; 88: 1574–81
   PubMed Web of Science ®Google Scholar
• Ueno K, Miyazono N, Inoue H, Miyake S, Nishida H, Nakajo M. Embolization of the hepatic falciform artery to prevent supraumbilical skin rash during transcatheter arterial chemoembolization for hepatocellular carcinoma. Cardiovasc Intervent Radiol 1995; 18: 183–5
   PubMed Web of Science ®Google Scholar
• Chan AO, Yuen MF, Hui CK, Tso WK, Lai CL. A prospective study regarding the complications of transcatheter intraarterial lipiodol chemoembolization in patients with hepatocellular carcinoma. Cancer 2002; 94: 1747–52
   PubMed Web of Science ®Google Scholar
• Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis—correlation in invasive breast carcinoma. N Engl J Med 1991; 324: 1–8
   PubMed Web of Science ®Google Scholar
• Folkman J. Angiogenesis and angiogenesis inhibition: an overview. Exs 1997; 79: 1–8
   PubMedGoogle Scholar
• Fiedler W, Graeven U, Ergun S, Verago S, Kilic N, Stockschlader M, et al. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. Blood 1997; 89: 1870–5
   PubMed Web of Science ®Google Scholar
• Aguayo A, Kantarjian H, Manshouri T, Gidel C, Estey E, Thomas D, et al. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood 2000; 96: 2240–5
   PubMed Web of Science ®Google Scholar
• Berse B, Brown LF, Van de Water L, Dvorak HF, Senger DR. Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors. Mol Biol Cell 1992; 3: 211–20
   PubMed Web of Science ®Google Scholar
• Folkman J, Shing Y. Angiogenesis. J Biol Chem 1992; 267: 10931–4
   PubMed Web of Science ®Google Scholar
• Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002; 29: 15–8
   PubMed Web of Science ®Google Scholar
• Wang B, Gao ZQ, Yan X. Correlative study of angiogenesis and dynamic contrast-enhanced magnetic resonance imaging features of hepatocellular carcinoma. Acta Radiol 2005; 46: 353–8
   PubMed Web of Science ®Google Scholar
• Brogi E, Schatteman G, Wu T, Kim EA, Varticovski L, Keyt B, et al. Hypoxia-induced paracrine regulation of vascular endothelial growth factor receptor expression. J Clin Invest 1996; 97: 469–76
   PubMed Web of Science ®Google Scholar
• Detmar M, Brown LF, Berse B, Jackman RW, Elicker BM, Dvorak HF, et al. Hypoxia regulates the expression of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) and its receptors in human skin. J Invest Dermatol 1997; 108: 263–8
   PubMed Web of Science ®Google Scholar
• Ferrara N. Vascular endothelial growth factor and the regulation of angiogenesis. Recent Prog Horm Res 2000;55:15–35; discussion 35–6.
   PubMedGoogle Scholar
• Yao DF, Wu XH, Zhu Y, Shi GS, Dong ZZ, Yao DB, et al. Quantitative analysis of vascular endothelial growth factor, microvascular density and their clinicopathologic features in human hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2005; 4: 220–6
   PubMedGoogle Scholar
• Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992; 359: 843–5
   PubMed Web of Science ®Google Scholar
• Kobayashi N, Ishii M, Ueno Y, Kisara N, Chida N, Iwasaki T, et al. Co-expression of Bcl-2 protein and vascular endothelial growth factor in hepatocellular carcinomas treated by chemoembolization. Liver 1999; 19: 25–31
   PubMedGoogle Scholar
• Biroccio A, Candiloro A, Mottolese M, Sapora O, Albini A, Zupi G, et al. Bcl-2 overexpression and hypoxia synergistically act to modulate vascular endothelial growth factor expression and in vivo angiogenesis in a breast carcinoma line. Faseb J 2000; 14: 652–60
   PubMed Web of Science ®Google Scholar
• Fernandez A, Udagawa T, Schwesinger C, Beecken W, Achilles-Gerte E, McDonnell T, et al. Angiogenic potential of prostate carcinoma cells overexpressing bcl-2. J Natl Cancer Inst 2001; 93: 208–13
   PubMedGoogle Scholar
• Iervolino A, Trisciuoglio D, Ribatti D, Candiloro A, Biroccio A, Zupi G, et al. Bcl-2 overexpression in human melanoma cells increases angiogenesis through VEGF mRNA stabilization and HIF-1-mediated transcriptional activity. Faseb J 2002; 16: 1453–5
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006; 24: 4293–300
   PubMed Web of Science ®Google Scholar
• Zhu AX. Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma. Cancer 2007; 26: 250–9
   Google Scholar
• Furuse J, Ishii H, Nakachi K, Suzuki E, Shimizu S, Nakajima K. Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. Cancer Sci 2008; 99: 159–65
   PubMed Web of Science ®Google Scholar
• Bracarda S, Caserta C, Sordini L, Rossi M, Hamzay A, Crino L. Protein kinase inhibitors in the treatment of renal cell carcinoma: sorafenib. Ann Oncol 2007; 18(Suppl 6)vi22–5
   PubMed Web of Science ®Google Scholar
• Flaherty KT. Sorafenib: delivering a targeted drug to the right targets. Expert Rev Anticancer Ther 2007; 7: 617–26
   PubMed Web of Science ®Google Scholar
• Llovet J, Ricci S, Mazzaferro V, Hilgard P, Raoul J, Zeuzem S, et al. For the SHARP Investigators Study Group. Sorafenib improves survival in advanced hepatocellular carcinoma (HCC): results of a phase III randomized placebo-controlled trial (SHARP trial). J Clin Oncol 2007; 25: LBA1
   Web of Science ®Google Scholar
• Folkman J. New perspectives in clinical oncology from angiogenesis research. Eur J Cancer 1996; 32: 2534–9
   Web of Science ®Google Scholar
• Huang ST, Yang RC, Lee PN, Yang SH, Liao SK, Chen TY, et al. Anti-tumor and anti-angiogenic effects of Phyllanthus urinaria in mice bearing Lewis lung carcinoma. Int Immunopharmacol 2006; 6: 870–9
   PubMed Web of Science ®Google Scholar
• Tanaka H, Taniguchi H, Mugitani T, Koishi Y, Masuyama M, Higashida T, et al. Intra-arterial administration of the angiogenesis inhibitor TNP-470 blocks liver metastasis in a rabbit model. Br J Cancer 1995; 72: 650–3
   PubMed Web of Science ®Google Scholar
• Ogawa H, Sato Y, Kondo M, Takahashi N, Oshima T, Sasaki F, et al. Combined treatment with TNP-470 and 5-fluorouracil effectively inhibits growth of murine colon cancer cells in vitro and liver metastasis in vivo. Oncol Rep 2000; 7: 467–72
   PubMed Web of Science ®Google Scholar
• Kin M, Torimura T, Ueno T, Nakamura T, Ogata R, Sakamoto M, et al. Angiogenesis inhibitor TNP-470 suppresses the progression of experimentally-induced hepatocellular carcinoma in rats. Int J Oncol 2000; 16: 375–82
   PubMed Web of Science ®Google Scholar